SanBio Company Limited engages in the development, production, and sale of regenerative cell medicines for the central nervous system in Japan and the United States. It develops SB623 that has completed a phase 2 clinical trial to treat traumatic brain injury. The company's research pipeline products also comprise SB623 for chronic disease, age-related macular degeneration, retinitis pigmentosa, spinal cord injury, Parkinson's disease, Alzheimer's disease, etc.; SB618 to treat peripheral nerve damage; SB308 for muscular dystrophy disease; MSC1 for cancer; and MSC2 for inflammatory disease and optic neuritis. The company was founded in 2001 and is headquartered in Tokyo, Japan.
Frequently asked questions
What sector does Sanbio Company Limited (4592) operate in?
Sanbio Company Limited belongs to the Healthcare sector and operates in the Biotechnology industry.
What is Sanbio Company Limited (4592) current stock price?
As of the latest data, Sanbio Company Limited stock price is ¥907, with a previous close of ¥877. Sanbio Company Limited gained ¥30 in the last trading session, representing a 3.42% increase.
What is Sanbio Company Limited (4592) current market capitalization?
Sanbio Company Limited market cap is approximately 70.78 billion.
What is Sanbio Company Limited (4592) Earnings Per Share (EPS)?
The trailing EPS is -¥53, and the forward EPS is -¥18.
What is Sanbio Company Limited (4592) EBITDA?
Sanbio Company Limited EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -949.32 million.
Does Sanbio Company Limited (4592) pay dividends?
No. Sanbio Company Limited does not pay a dividend.
When is Sanbio Company Limited (4592) next earnings report?
Sanbio Company Limited is expected to release its next earnings report on July 31, 2026.
What is Sanbio Company Limited (4592) beta (volatility) score?
Sanbio Company Limited has a beta of 0.282, indicating lower volatility than the overall market.
